Life Scientist > Lab Technology

Australian biotechs must merge or perish: Ernst and Young

27 February, 2002 by Tanya Hollis

Australia's biotechnology companies will have to merge or perish, according to leading industry analyst Ernst and Young.

Xenome chief flags industry insurance fears

27 February, 2002 by Pete Young

There are fears the current insurance industry upheaval will force some biotechs to the wall unless the Gene Technology Act 2000 is overhauled.

CSIRO lifting its game: Garrett

26 February, 2002 by Tanya Hollis

CSIRO was well on its way to addressing the raft of serious problems outlined in a confidential internal report, the organisation's chief has claimed.

Cone snail proving to be companies' best friend

26 February, 2002 by Melissa Trudinger

The cone snail, a marine snail from the Great Barrier Reef, is proving to be a vaulable ally in pain management drug research.

Consolidation contributes to Agenix half-year profit

26 February, 2002 by Daniella Goldberg

Agenix Limited (ASX: AGH) has announced a 435 per cent increase in after-tax profit to $1.7 million for the six months to December 31, 2001.

Go west, young biotech entrepreneur

25 February, 2002 by Daniella Goldberg

BioWest, the first directory for the biotechnology industry in western Sydney, is being launched today by Kim Yeadon, NSW Minister for Western Sydney.

Thrombogenix to change its name

22 February, 2002 by Tanya Hollis

Kinase and blood-clotting disease research group Thrombogenix is within weeks of a name change intended to reflect a broader focus.

We'll float when we're ready, says PSL chief

22 February, 2002 by Daniella Goldberg

Sydney-based company Proteome Systems Limited (PSL) has participated in a new round of capital raising as speculation mounts about the timing of the company's public float.

'Poor performer' biotechs urge shareholders to take the long view

22 February, 2002 by Pete Young

Two biotech companies, Biota Holdings and Progen Industries, have popped up on the Australian Shareholders Association's 2002 list of 'Poor Performers'.

Growth for GroPep in Biotech Australia buy

21 February, 2002 by Tanya Hollis

Cell growth factor company GroPep is expecting to record a profit within six months after finalising its purchase of Biotech Australia Group.

Queensland biotech's reclusive benefactor

21 February, 2002 by Pete Young

Self-made billionaire and secretive philanthropist Charles Feeney appears to have a soft spot for Queensland's biotechnology sector.

Ciphergen teams up on AIDS research using protein chips

20 February, 2002 by John Dodge

US company Ciphergen Biosystems has signed two joint development agreements that will call on its protein chips to find out why AIDS does not progress in a small percentage of HIV-infected individuals.

Distributed computing to be used for anthrax research

20 February, 2002 by Peter Sayer

In your idle moments, your computer can now join the search for a cure for anthrax.

Light science aids life science

19 February, 2002 by Pete Young

A $1.6 million research centre in Queensland will put advanced photonics tools like laser tweezers in the hands of life science researchers.

Optiscan counts the cash in wake of Pentax deal

19 February, 2002 by Tanya Hollis

OPTISCAN has banked its first installment from the $AUD19.6 million Pentax endomicroscope deal announced last week.

  • All content Copyright © 2022 Westwick-Farrow Pty Ltd